LifeScience BioSimilar

Alteogen Subsidiary Altos Biologics Submits MAA to EMA for ALT-L9 Aflibercept Biosimilar

Alteogen Inc. announced that its subsidiary, Altos Biologics Inc. has submitted Marketing Authorization Application (MAA) to the European Medicines Ag...

 July 02, 2024 | News

FDA Approves Bkemv as First Interchangeable Biosimilar to Soliris

U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare di...

 May 29, 2024 | News

Henlius Biotech and Organon Receive EMA Validation for Denosumab Biosimilar HLX14

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing autho...

 May 27, 2024 | News

Teva Pharmaceuticals and mAbxience Forge Global Strategic Partnership for Oncology Biosimilar Development

Teva and mAbxience enter into a strategic global partnership for in-licensing of an oncology biosimilar candidate Agreement signals a major step i...

 April 05, 2024 | News

Biocon Biologics Teams Up with Sandoz Australia for Biosimilar Trastuzumab and Bevacizumab

Under the agreement, Sandoz will distribute the Biocon Biologics' brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), and facilita...

 February 09, 2024 | News

Glenmark Launches First Biosimilar of Liraglutide, a Popular Anti-Diabetic Drug in India

  ‐ The anti‐diabetic biosimilar has been launched under the brand name Lirafit™, and is indicated for improving glycemic control in adult ...

 January 03, 2024 | News

Biocon Biologics Successfully Integrates Acquired Biosimilars Business Across 120 Countries

Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully conc...

 December 19, 2023 | News

Biocon Biologics Completes Viatris Biosimilar Integration in 31 European Countries.

Following the acquisition of substantially all of the global biosimilar business of Viatris in November 2022, and the related integration of over...

 December 01, 2023 | News

EirGenix's Breast Cancer Biosimilar Receives Marketing Authorization by EC

The marketing authorization in the EU will cover the treatment of human epidermal growth factor receptor 2 positive (HER2-positive) breast cancer and metas...

 November 24, 2023 | News

Chime Biologics Partners with Korea Kings Pharm for Biosimilar Launch

Chime Biologics, a leading CDMO that enables its partners' success in biologics, announced a strategic cooperation with Kings Pharm. According to the agre...

 September 26, 2023 | News

Mabxience and Abbott Forge Strategic Deal to Expand Biosimilars Access in Emerging Markets

Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia and Middle East and Africa mAbxience Holdi...

 September 21, 2023 | News

BioRay's Zuberitamab (Anruixi®) First Domestic Anti-CD20 Antibody Approved in China

In preclinical studies, Anruixi® showed stronger antibody-dependent cell-mediated cytotoxicity (ADCC), a larger volume of distribution at steady state,...

 September 14, 2023 | News

Celltrion Celebrates a Decade of Biosimilar Innovation in Europe

Marking 10 years since the European Medicines Agency (EMA) approved the world’s first monoclonal antibody biosimilar infliximab, for all indication...

 September 11, 2023 | News

Biocon Biologics Expands Global Presence, Completes Viatris Biosimilars Integration in North America Ahead of Schedule.

To further strengthen its leadership position in the global biosimilars industry and provide complete end-to-end capabilities to patients and customers, Bi...

 September 07, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in